lilly retatrutide trial ESC 2024: improves lipid and cardiovascular risk profile in Phase II Eli Lilly's retatrutide shows efficacy

Additionally, rapid weight loss associated with these medications might sometimes precipitate headaches through various metabolic changes, though this mechanism requires further study

However, it is considered an important risk factor for weight gain ( Figure 1 )

In rats and mice, the GLP-1RA/tesaglitazar conjugate showed comparable pharmacokinetics relative to the GLP-1RA, including half-life ( T 1/2 ), maximum plasma concentration ( C max ), time for maximal plasma concentration ( T max ) and area under the curve (AUC) from zero to last valid measurable concentration-time point (AUC 0-t ) (Extended Data Fig

comparators had no GLP-1 prescriptions